Global Human Coagulation Factor VIII Market 2024 by Manufacturers, Regions, Type and Application, Forecast to 2030

Global Human Coagulation Factor VIII Market 2024 by Manufacturers, Regions, Type and Application, Forecast to 2030

Human Coagulation Factor VIII is an essential blood-clotting protein, also known as anti-hemophilic factor (AHF). In humans, factor VIII is encoded by the F8 gene, defects in this gene results in hemophilia A. Human Coagulation Factor VIII concentrated from donated blood plasma (Aafact or Alphanate, Monoclate-P®), or alternatively recombinant Human Coagulation Factor VIII can be given to hemophiliacs to restore hemostasis.

According to our (Global Info Research) latest study, the global Human Coagulation Factor VIII market size was valued at US$ 11250 million in 2023 and is forecast to a readjusted size of USD 17000 million by 2030 with a CAGR of 6.2% during review period.

Global Human Coagulation Factor VIII key players include Baxter, Bayer, CSL, Pfizer, Biogen, etc. Global top five manufacturers hold a share about 80%. North America is the largest market, with a share about 60%, followed by Europe, with a share about 30 percent. In terms of product, Recombinant Factor VIII is the largest segment, with a share about 65%. And in terms of application, the largest application is Hemophilia A, followed by Spontanous / Trauma, Surgical, etc.

This report is a detailed and comprehensive analysis for global Human Coagulation Factor VIII market. Both quantitative and qualitative analyses are presented by manufacturers, by region & country, by Type and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2024, are provided.

Key Features:

Global Human Coagulation Factor VIII market size and forecasts, in consumption value ($ Million), sales quantity (K Bottles), and average selling prices (USD/Bottle), 2019-2030

Global Human Coagulation Factor VIII market size and forecasts by region and country, in consumption value ($ Million), sales quantity (K Bottles), and average selling prices (USD/Bottle), 2019-2030

Global Human Coagulation Factor VIII market size and forecasts, by Type and by Application, in consumption value ($ Million), sales quantity (K Bottles), and average selling prices (USD/Bottle), 2019-2030

Global Human Coagulation Factor VIII market shares of main players, shipments in revenue ($ Million), sales quantity (K Bottles), and ASP (USD/Bottle), 2019-2024

The Primary Objectives in This Report Are:

To determine the size of the total market opportunity of global and key countries

To assess the growth potential for Human Coagulation Factor VIII

To forecast future growth in each product and end-use market

To assess competitive factors affecting the marketplace

This report profiles key players in the global Human Coagulation Factor VIII market based on the following parameters - company overview, sales quantity, revenue, price, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Shire (Baxter), Bayer, CSL, Pfizer, Grifols, Biogen, Octapharma, NovoNordisk, Greencross, Kedrion, etc.

This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.

Market Segmentation

Human Coagulation Factor VIII market is split by Type and by Application. For the period 2019-2030, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of volume and value. This analysis can help you expand your business by targeting qualified niche markets.

Market segment by Type
Recombinant Factor VIII
Plasma-derived Factor VIII

Market segment by Application
Hemophilia A
Spontanous / Trauma
Surgical
Other

Major players covered
Shire (Baxter)
Bayer
CSL
Pfizer
Grifols
Biogen
Octapharma
NovoNordisk
Greencross
Kedrion
BPL
Hualan Bio
RAAS

Market segment by region, regional analysis covers

North America (United States, Canada, and Mexico)

Europe (Germany, France, United Kingdom, Russia, Italy, and Rest of Europe)

Asia-Pacific (China, Japan, Korea, India, Southeast Asia, and Australia)

South America (Brazil, Argentina, Colombia, and Rest of South America)

Middle East & Africa (Saudi Arabia, UAE, Egypt, South Africa, and Rest of Middle East & Africa)

The content of the study subjects, includes a total of 15 chapters:

Chapter 1, to describe Human Coagulation Factor VIII product scope, market overview, market estimation caveats and base year.

Chapter 2, to profile the top manufacturers of Human Coagulation Factor VIII, with price, sales quantity, revenue, and global market share of Human Coagulation Factor VIII from 2019 to 2024.

Chapter 3, the Human Coagulation Factor VIII competitive situation, sales quantity, revenue, and global market share of top manufacturers are analyzed emphatically by landscape contrast.

Chapter 4, the Human Coagulation Factor VIII breakdown data are shown at the regional level, to show the sales quantity, consumption value, and growth by regions, from 2019 to 2030.

Chapter 5 and 6, to segment the sales by Type and by Application, with sales market share and growth rate by Type, by Application, from 2019 to 2030.

Chapter 7, 8, 9, 10 and 11, to break the sales data at the country level, with sales quantity, consumption value, and market share for key countries in the world, from 2019 to 2024.and Human Coagulation Factor VIII market forecast, by regions, by Type, and by Application, with sales and revenue, from 2025 to 2030.

Chapter 12, market dynamics, drivers, restraints, trends, and Porters Five Forces analysis.

Chapter 13, the key raw materials and key suppliers, and industry chain of Human Coagulation Factor VIII.

Chapter 14 and 15, to describe Human Coagulation Factor VIII sales channel, distributors, customers, research findings and conclusion.